ForwardLooking Statements This press release contains forwardlooking statements about the business prospects of BioMarin Pharmaceutical Inc including without limitation statements about i the development of BioMarins valoctocogene roxaparvovec program generally ii further regulatory interactions with the FDA valoctocogene roxaparvovec iii possible requirements for approval of valoctocogene roxaparvovec including the suitability of Study 270301 to meet such requirements iv the conduct of ongoing clinical trials for valoctocogene roxaparvovec v and the continued review of the Marketing Authorization Application for valoctocogene roxaparvovec by the European Medicines Agency